Program
zemocimig
A development code. Also written as “NXT007”.
Its studies are mostly in Hemophilia A, led by Hoffmann-La Roche.
Furthest: phase 3, since Feb 11, 20265 company-led studies, 4 open or runningNext primary completion: Sep 23, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 54 open or running | phase 3since Feb 11, 2026 | Aug 4, 2023 | Sep 23, 2027phase 3 · NCT07416526 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6512 zemocimig (NXT007)
, phase 3, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 4, 2023First study: phase 2 study in Hemophilia AFirst studyNCT05987449 · 60 planned · United States, Canada, Italy and more
- Dec 11, 2023Phase 1 study in Healthy Male ParticipantsNCT06189508 · 48 enrolled · New Zealand
- Feb 11, 20262 phase 3 studies in Hemophilia APhase 3 reachedNCT07416604, NCT07416526
- Sep 17, 2026Phase 3 study in Hemophilia ANCT07838194 · 50 planned · Japan
Ahead
- Sep 23, 2027Primary completion: phase 3 study in Hemophilia ANCT07416526
- Feb 29, 2028Primary completion: phase 3 study in Hemophilia ANCT07416604
- Sep 30, 2028Primary completion: phase 3 study in Hemophilia ANCT07838194
- Dec 11, 2033Primary completion: phase 2 study in Hemophilia ANCT05987449
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07838194Hemophilia A · Japan | 3 | Recruiting | Sep 30, 2028 | 50 |
| NCT07416604Hemophilia A · United States, Argentina, Australia and more | 3 | Recruiting | Feb 29, 2028 | 360 |
| NCT07416526Hemophilia A · United States, Argentina, Austria and more | 3 | Recruiting | Sep 23, 2027 | 138 |
| NCT06189508Healthy Male Participants · New Zealand | 1 | Completed | Dec 22, 2024 | 48 |
| NCT05987449Hemophilia A · United States, Canada, Italy and more | 2 | Recruiting | Dec 11, 2033 | 60 |
How it is read
Names in the registry
- “NXT007”, 5 entries
Codes read as this program: NXT007.
Conditions, from the studies’ own filings
- Hemophilia A, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.